Incretin-Based Therapies Role in COVID-19 Era: Evolving Insights

27Citations
Citations of this article
136Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The current coronavirus disease 2019 (COVID-19) pandemic has led the scientific community to breach new frontiers in the understanding of human physiology and disease pathogenesis. It has been hypothesized that the human dipeptidyl peptidase 4 (DPP4) enzyme receptor may be a functional target for the spike proteins of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2). Since DPP4-inhibitors are currently used for the treatment of patients with type-2 diabetes (T2DM), there is currently high interest in the possibility that these agents, or incretin-based therapies (IBTs) in general, may be of benefit against the new coronavirus infection. Diabetes is associated with increased COVID-19 severity and mortality, and accumulating evidence suggests that IBTs may favorably alter the clinical course of SARS-CoV-2 infection due to their inherent mechanisms of action. Further research into prognostic variables associated with various antidiabetic treatment regimens, and in particular the IBT, in patients with T2DM affected by the COVID-19 pandemic is therefore warranted.

Author supplied keywords

Cite

CITATION STYLE

APA

Stoian, A. P., Papanas, N., Prazny, M., Rizvi, A. A., & Rizzo, M. (2020, November 1). Incretin-Based Therapies Role in COVID-19 Era: Evolving Insights. Journal of Cardiovascular Pharmacology and Therapeutics. SAGE Publications Ltd. https://doi.org/10.1177/1074248420937868

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free